Effect of narrow spectrum versus selective kinase inhibitors on the intestinal proinflammatory immune tesponse in ulcerative colitis

Paolo Biancheri, Martyn R. Foster, Matthew C.T. Fyfe, Thomas T. MacDonald, Sameer Sirohi, Yemisi Solanke, Eleanor Wood, Adele Rowley, Steve Webber, Claire A. Walshe

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
7 Downloads (Pure)


Background: Kinases are key mediators of inflammation, highlighting the potential of kinase inhibitors as treatments for inflammatory disorders. Selective kinase inhibitors, however, have proved disappointing, particularly in the treatment of rheumatoid arthritis and inflammatory bowel disease. Consequently, to improve efficacy, attention has turned to multikinase inhibition.

Methods: The activity of a narrow spectrum kinase inhibitor, TOP1210, has been compared with selective kinase inhibitors (BIRB-796, dasatinib and BAY-61-3606) in a range of kinase assays, inflammatory cell assays, and in inflamed biopsies from patients with ulcerative colitis (UC). Effects on recombinant P38α, Src, and Syk kinase activities were assessed using Z-lyte assays (Invitrogen, Paisley, United Kingdom). Anti-inflammatory effects were assessed by measurement of proinflammatory cytokine release from peripheral blood mononuclear cells, primary macrophages, HT29 cells, inflamed colonic UC biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa.

Results: TOP1210 potently inhibits P38α, Src, and Syk kinase activities. Similarly, TOP1210 demonstrates potent inhibitory activity against proinflammatory cytokine release in each of the cellular assays and the inflamed colonic UC biopsies and myofibroblasts isolated from inflamed colonic UC mucosa. Generally, the selective kinase inhibitors showed limited and weaker activity in the cellular assays compared with the broad inhibitory profile of TOP1210. However, combination of the selective inhibitors led to improved efficacy and potency in both cellular and UC biopsy assays.

Conclusions: Targeted, multikinase inhibition with TOP1210 leads to a broad efficacy profile in both the innate and adaptive immune responses, with significant advantages over existing selective kinase approaches, and potentially offers a much improved therapeutic benefit in inflammatory bowel disease.
Original languageEnglish
Pages (from-to)1306-1315
Number of pages10
JournalInflammatory Bowel Diseases
Issue number6
Early online date22 Apr 2016
Publication statusPublished - Jun 2016


  • narrow spectrum kinase inhibitor
  • TOP1210
  • ulcerative colitis

Cite this